Jul 2, 2024
|
To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
|
Jun 28, 2024
|
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
|
May 30, 2024
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
May 22, 2024
|
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
|
May 21, 2024
|
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
|
May 16, 2024
|
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
|
May 14, 2024
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
May 7, 2024
|
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
|
May 2, 2024
|
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
|
May 1, 2024
|
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
|